English

ANI PHARMACEUTICALS INC

EDGAR

ANIP Quarterly report (10-Q) · filed 2026-08-07

Annual consolidated revenue for 2025: about USD 883.4M, using the latest reported figures. The previous period, 2024, was about USD 614.4M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

266 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 266044000 USD Source

Operating margin

15.21%

2026 Q2 · %

Exact inputs and evidence

Operating Income: 40460000 USD Source
Revenue: 266044000 USD Source

Operating cash flow

56.7 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: 115044000 USD Source
Operating Cash Flow: 58375000 USD Source

Free cash flow

53.6 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: 115044000 USD Source
Operating Cash Flow: 58375000 USD Source
Capital Expenditure: 9128000 USD Source
Capital Expenditure: 6074000 USD Source

Cash and cash equivalents: 360 million USD 2026-06-30 Source
Exact value

360212000 USD
Long-term debt including current maturities: 134 million USD 2018-09-30 Source
Exact value

134100000 USD
Shares outstanding: 22.5 million shares 2025-12-31 Source
Exact value

22491281 shares

Reported share-count change

6.55% · 1.38 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

21108152 shares · 2024-12-31· Source
22491281 shares · 2025-12-31· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-07.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 9 of 11 periods available· newest 2025-12-31
Operating income: 9 of 11 periods available· newest 2025-12-31
Net income: 9 of 11 periods available· newest 2025-12-31
Operating cash flow: 9 of 11 periods available· newest 2025-12-31
Capital expenditure: 9 of 11 periods available· newest 2025-12-31
Total assets: 8 of 11 periods available· newest 2025-12-31
Total liabilities: 8 of 11 periods available· newest 2025-12-31
Current assets: 8 of 11 periods available· newest 2025-12-31
Current liabilities: 8 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 10 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 3 of 11 periods available· newest 2017-12-31
Shares outstanding: 2 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+43.8%

Prior period

USD 614.38 million

2024-01-01 – 2024-12-31
Current period

USD 883.37 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

883366000 − 614376000 = 268990000 USD

614376000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
883366000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · ANI PHARMACEUTICALS INC · 2025-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Year-over-year change in Revenue: 268990000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 883366000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/anip-20251231.htm#2774533 Filing: 000102302426000014 Input fundies:Revenue: 614376000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/anip-20251231.htm#2775371 Filing: 000102302426000014
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 96.86 million

Prior period

−USD 18.52 million

2024-01-01 – 2024-12-31
Current period

USD 78.34 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

78337000 − -18522000 = 96859000 USD

-18522000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
78337000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · ANI PHARMACEUTICALS INC · 2025-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Year-over-year change in Net income: 96859000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: 78337000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/anip-20251231.htm#1441778 Filing: 000102302426000014 Input fundies:NetIncome: -18522000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/anip-20251231.htm#1377146 Filing: 000102302426000014
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+189.3%

Prior period

USD 64.02 million

2024-01-01 – 2024-12-31
Current period

USD 185.23 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

185225000 − 64017000 = 121208000 USD

64017000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
185225000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · ANI PHARMACEUTICALS INC · 2025-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Year-over-year change in Operating cash flow: 121208000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 185225000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/anip-20251231.htm#1500357 Filing: 000102302426000014 Input fundies:OperatingCashFlow: 64017000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/anip-20251231.htm#1501004 Filing: 000102302426000014
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-14.8%

Prior period

USD 16.24 million

2024-01-01 – 2024-12-31
Current period

USD 13.84 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

13835000 − 16236000 = -2401000 USD

16236000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
13835000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · ANI PHARMACEUTICALS INC · 2025-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Year-over-year change in Capital expenditure: -2401000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 13835000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/anip-20251231.htm#1507552 Filing: 000102302426000014 Input fundies:CapitalExpenditure: 16236000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/anip-20251231.htm#1508142 Filing: 000102302426000014
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 883.37 million 100% of revenue
Operating costs Derived USD 772.27 million 87% of revenue
Operating income USD 111.09 million 13% of revenue
Tax, interest and other Derived USD 32.76 million 3.7% of revenue
Net income USD 78.34 million 8.9% of revenue

Cash

Operating cash flow USD 185.23 million 21% of revenue
Capital expenditure USD 13.84 million 1.6% of revenue
Free cash flow Derived USD 171.39 million 19% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2015 20%23%57%
2016 13%84%
2017 Net loss: net income was −0.6% of revenue.
2018 9.9%82%
2021 Operating loss: operating costs were 118% of revenue.
2022 Operating loss: operating costs were 111% of revenue.
2023 90%
2024 Net loss: net income was −3% of revenue.
2025 87%

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2015 2015-01-01 – 2015-12-31	76322000	43622000 Derived	32700000	17325000 Derived	15375000	15081000 Derived	Source 2015-01-01 – 2015-12-31: 76322000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: 32700000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: 15375000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: 17264000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 2183000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	128622000	108543000 Derived	20079000	16145000 Derived	3934000	22906000 Derived	Source 2016-01-01 – 2016-12-31: 128622000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: 20079000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: 3934000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: 27472000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 4566000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	176842000	148513000 Derived	28329000	29405000 Derived	-1076000	29050000 Derived	Source 2017-01-01 – 2017-12-31: 176842000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: 28329000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -1076000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: 39419000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 10369000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	201576000	166217000 Derived	35359000	19865000 Derived	15494000	61331000 Derived	Source 2018-01-01 – 2018-12-31: 201576000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: 35359000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: 15494000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: 67074000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 5743000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	216136000	255929000 Derived	-39793000	2810000 Derived	-42603000	765000 Derived	Source 2021-01-01 – 2021-12-31: 216136000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -39793000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -42603000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: 3322000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 2557000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	316385000	351668000 Derived	-35283000	12613000 Derived	-47896000	-40079000 Derived	Source 2022-01-01 – 2022-12-31: 316385000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -35283000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -47896000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -31203000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 8876000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	486816000	439845000 Derived	46971000	28192000 Derived	18779000	110091000 Derived	Source 2023-01-01 – 2023-12-31: 486816000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: 46971000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: 18779000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: 118959000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 8868000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	614376000	613792000 Derived	584000	19106000 Derived	-18522000	47781000 Derived	Source 2024-01-01 – 2024-12-31: 614376000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: 584000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -18522000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: 64017000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 16236000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	883366000	772273000 Derived	111093000	32756000 Derived	78337000	171390000 Derived	Source 2025-01-01 – 2025-12-31: 883366000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: 111093000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: 78337000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: 185225000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 13835000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 883.4M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Revenue	76322000	Revenue: 76322000 Open source
20162016-12-31	Revenue	128622000	Revenue: 128622000 Open source
20172017-12-31	Revenue	176842000	Revenue: 176842000 Open source
20182018-12-31	Revenue	201576000	Revenue: 201576000 Open source
20212021-12-31	Revenue	216136000	Revenue: 216136000 Open source
20222022-12-31	Revenue	316385000	Revenue: 316385000 Open source
20232023-12-31	Revenue	486816000	Revenue: 486816000 Open source
20242024-12-31	Revenue	614376000	Revenue: 614376000 Open source
20252025-12-31	Revenue	883366000	Revenue: 883366000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

43.8% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Year over year	No prior comparable period	Revenue: 76322000 Open source
20162016-12-31	Year over year	68.5%	Revenue: 128622000 Open source Revenue: 76322000 Open source
20172017-12-31	Year over year	37.5%	Revenue: 176842000 Open source Revenue: 128622000 Open source
20182018-12-31	Year over year	14%	Revenue: 201576000 Open source Revenue: 176842000 Open source
20212021-12-31	Year over year	No prior comparable period	Revenue: 216136000 Open source
20222022-12-31	Year over year	46.4%	Revenue: 316385000 Open source Revenue: 216136000 Open source
20232023-12-31	Year over year	53.9%	Revenue: 486816000 Open source Revenue: 316385000 Open source
20242024-12-31	Year over year	26.2%	Revenue: 614376000 Open source Revenue: 486816000 Open source
20252025-12-31	Year over year	43.8%	Revenue: 883366000 Open source Revenue: 614376000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin 12.6% 2025

Net margin 8.9% 2025

Free cash flow margin 19.4% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Operating margin	42.8%	Operating Income: 32700000 Open source Revenue: 76322000 Open source
20162016-12-31	Operating margin	15.6%	Operating Income: 20079000 Open source Revenue: 128622000 Open source
20172017-12-31	Operating margin	16%	Operating Income: 28329000 Open source Revenue: 176842000 Open source
20182018-12-31	Operating margin	17.5%	Operating Income: 35359000 Open source Revenue: 201576000 Open source
20212021-12-31	Operating margin	-18.4%	Operating Income: -39793000 Open source Revenue: 216136000 Open source
20222022-12-31	Operating margin	-11.2%	Operating Income: -35283000 Open source Revenue: 316385000 Open source
20232023-12-31	Operating margin	9.6%	Operating Income: 46971000 Open source Revenue: 486816000 Open source
20242024-12-31	Operating margin	0.1%	Operating Income: 584000 Open source Revenue: 614376000 Open source
20252025-12-31	Operating margin	12.6%	Operating Income: 111093000 Open source Revenue: 883366000 Open source
20152015-12-31	Net margin	20.1%	Net Income: 15375000 Open source Revenue: 76322000 Open source
20162016-12-31	Net margin	3.1%	Net Income: 3934000 Open source Revenue: 128622000 Open source
20172017-12-31	Net margin	-0.6%	Net Income: -1076000 Open source Revenue: 176842000 Open source
20182018-12-31	Net margin	7.7%	Net Income: 15494000 Open source Revenue: 201576000 Open source
20212021-12-31	Net margin	-19.7%	Net Income: -42603000 Open source Revenue: 216136000 Open source
20222022-12-31	Net margin	-15.1%	Net Income: -47896000 Open source Revenue: 316385000 Open source
20232023-12-31	Net margin	3.9%	Net Income: 18779000 Open source Revenue: 486816000 Open source
20242024-12-31	Net margin	-3%	Net Income: -18522000 Open source Revenue: 614376000 Open source
20252025-12-31	Net margin	8.9%	Net Income: 78337000 Open source Revenue: 883366000 Open source
20152015-12-31	Free cash flow margin	19.8%	Revenue: 76322000 Open source Operating Cash Flow: 17264000 Open source Capital Expenditure: 2183000 Open source
20162016-12-31	Free cash flow margin	17.8%	Revenue: 128622000 Open source Operating Cash Flow: 27472000 Open source Capital Expenditure: 4566000 Open source
20172017-12-31	Free cash flow margin	16.4%	Revenue: 176842000 Open source Operating Cash Flow: 39419000 Open source Capital Expenditure: 10369000 Open source
20182018-12-31	Free cash flow margin	30.4%	Revenue: 201576000 Open source Operating Cash Flow: 67074000 Open source Capital Expenditure: 5743000 Open source
20212021-12-31	Free cash flow margin	0.4%	Revenue: 216136000 Open source Operating Cash Flow: 3322000 Open source Capital Expenditure: 2557000 Open source
20222022-12-31	Free cash flow margin	-12.7%	Revenue: 316385000 Open source Operating Cash Flow: -31203000 Open source Capital Expenditure: 8876000 Open source
20232023-12-31	Free cash flow margin	22.6%	Revenue: 486816000 Open source Operating Cash Flow: 118959000 Open source Capital Expenditure: 8868000 Open source
20242024-12-31	Free cash flow margin	7.8%	Revenue: 614376000 Open source Operating Cash Flow: 64017000 Open source Capital Expenditure: 16236000 Open source
20252025-12-31	Free cash flow margin	19.4%	Revenue: 883366000 Open source Operating Cash Flow: 185225000 Open source Capital Expenditure: 13835000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD 185.2M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Operating cash flow	17264000	Operating Cash Flow: 17264000 Open source
20162016-12-31	Operating cash flow	27472000	Operating Cash Flow: 27472000 Open source
20172017-12-31	Operating cash flow	39419000	Operating Cash Flow: 39419000 Open source
20182018-12-31	Operating cash flow	67074000	Operating Cash Flow: 67074000 Open source
20212021-12-31	Operating cash flow	3322000	Operating Cash Flow: 3322000 Open source
20222022-12-31	Operating cash flow	-31203000	Operating Cash Flow: -31203000 Open source
20232023-12-31	Operating cash flow	118959000	Operating Cash Flow: 118959000 Open source
20242024-12-31	Operating cash flow	64017000	Operating Cash Flow: 64017000 Open source
20252025-12-31	Operating cash flow	185225000	Operating Cash Flow: 185225000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD 171.4M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Free cash flow	15081000	Operating Cash Flow: 17264000 Open source Capital Expenditure: 2183000 Open source
20162016-12-31	Free cash flow	22906000	Operating Cash Flow: 27472000 Open source Capital Expenditure: 4566000 Open source
20172017-12-31	Free cash flow	29050000	Operating Cash Flow: 39419000 Open source Capital Expenditure: 10369000 Open source
20182018-12-31	Free cash flow	61331000	Operating Cash Flow: 67074000 Open source Capital Expenditure: 5743000 Open source
20212021-12-31	Free cash flow	765000	Operating Cash Flow: 3322000 Open source Capital Expenditure: 2557000 Open source
20222022-12-31	Free cash flow	-40079000	Operating Cash Flow: -31203000 Open source Capital Expenditure: 8876000 Open source
20232023-12-31	Free cash flow	110091000	Operating Cash Flow: 118959000 Open source Capital Expenditure: 8868000 Open source
20242024-12-31	Free cash flow	47781000	Operating Cash Flow: 64017000 Open source Capital Expenditure: 16236000 Open source
20252025-12-31	Free cash flow	171390000	Operating Cash Flow: 185225000 Open source Capital Expenditure: 13835000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

62.5% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Liabilities / assets	43.9%	Total Liabilities: 125183000 Open source Total Assets: 285265000 Open source
20162016-12-31	Liabilities / assets	47.5%	Total Liabilities: 153216000 Open source Total Assets: 322864000 Open source
20172017-12-31	Liabilities / assets	57.6%	Total Liabilities: 237382000 Open source Total Assets: 412138000 Open source
20182018-12-31	Liabilities / assets	54.2%	Total Liabilities: 233341000 Open source Total Assets: 430604000 Open source
2021-12-31	Liabilities / assets	Not reported	No source recorded
20222022-12-31	Liabilities / assets	55.5%	Total Liabilities: 421547000 Open source Total Assets: 760087000 Open source
20232023-12-31	Liabilities / assets	49.4%	Total Liabilities: 446823000 Open source Total Assets: 904422000 Open source
20242024-12-31	Liabilities / assets	66.6%	Total Liabilities: 855939000 Open source Total Assets: 1284469000 Open source
20252025-12-31	Liabilities / assets	62.5%	Total Liabilities: 899653000 Open source Total Assets: 1440377000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

2.71× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Current assets / current liabilities	16.38×	Current Assets: 192583000 Open source Current Liabilities: 11756000 Open source
20162016-12-31	Current assets / current liabilities	3.22×	Current Assets: 103007000 Open source Current Liabilities: 31948000 Open source
20172017-12-31	Current assets / current liabilities	3.35×	Current Assets: 131605000 Open source Current Liabilities: 39228000 Open source
20182018-12-31	Current assets / current liabilities	0.92×	Current Assets: 152877000 Open source Current Liabilities: 165549000 Open source
2021-12-31	Current assets / current liabilities	Not reported	No source recorded
20222022-12-31	Current assets / current liabilities	3.46×	Current Assets: 344261000 Open source Current Liabilities: 99439000 Open source
20232023-12-31	Current assets / current liabilities	3.57×	Current Assets: 519816000 Open source Current Liabilities: 145477000 Open source
20242024-12-31	Current assets / current liabilities	2.72×	Current Assets: 528456000 Open source Current Liabilities: 194452000 Open source
20252025-12-31	Current assets / current liabilities	2.71×	Current Assets: 753117000 Open source Current Liabilities: 278112000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2015 2015-01-01 – 2015-12-31	USD 15.38 million Exact value Exact value: 15375000 USD 2015-01-01 – 2015-12-31: 15375000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ANI PHARMACEUTICALS INC · 2015-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Net Income: 15375000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: 15375000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000114420418011197/anip-20171231.xml#366728 Filing: 000114420418011197 The citation records this snapshot. The page link may show a newer release later.	USD 17.26 million Exact value Exact value: 17264000 USD 2015-01-01 – 2015-12-31: 17264000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ANI PHARMACEUTICALS INC · 2015-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Operating Cash Flow: 17264000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 17264000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000114420418011197/anip-20171231.xml#622816 Filing: 000114420418011197 The citation records this snapshot. The page link may show a newer release later.	USD 2.18 million Exact value Exact value: 2183000 USD 2015-01-01 – 2015-12-31: 2183000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ANI PHARMACEUTICALS INC · 2015-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Capital Expenditure: 2183000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2183000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000114420418011197/anip-20171231.xml#623194 Filing: 000114420418011197 The citation records this snapshot. The page link may show a newer release later.	USD 15.08 million Calculation and evidence 17264000 − 2183000 USD Exact free cash flow: 15081000 USD 2015-01-01 – 2015-12-31: 17264000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 2183000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ANI PHARMACEUTICALS INC · 2015-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Free cash flow: 15081000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 17264000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000114420418011197/anip-20171231.xml#622816 Filing: 000114420418011197 Input fundies:CapitalExpenditure: 2183000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000114420418011197/anip-20171231.xml#623194 Filing: 000114420418011197 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	USD 3.93 million Exact value Exact value: 3934000 USD 2016-01-01 – 2016-12-31: 3934000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ANI PHARMACEUTICALS INC · 2016-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Net Income: 3934000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: 3934000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000114420419010541/anip-20181231.xml#579475 Filing: 000114420419010541 The citation records this snapshot. The page link may show a newer release later.	USD 27.47 million Exact value Exact value: 27472000 USD 2016-01-01 – 2016-12-31: 27472000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ANI PHARMACEUTICALS INC · 2016-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Operating Cash Flow: 27472000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 27472000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000114420419010541/anip-20181231.xml#305065 Filing: 000114420419010541 The citation records this snapshot. The page link may show a newer release later.	USD 4.57 million Exact value Exact value: 4566000 USD 2016-01-01 – 2016-12-31: 4566000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ANI PHARMACEUTICALS INC · 2016-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Capital Expenditure: 4566000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4566000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000114420419010541/anip-20181231.xml#306235 Filing: 000114420419010541 The citation records this snapshot. The page link may show a newer release later.	USD 22.91 million Calculation and evidence 27472000 − 4566000 USD Exact free cash flow: 22906000 USD 2016-01-01 – 2016-12-31: 27472000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 4566000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ANI PHARMACEUTICALS INC · 2016-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Free cash flow: 22906000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 27472000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000114420419010541/anip-20181231.xml#305065 Filing: 000114420419010541 Input fundies:CapitalExpenditure: 4566000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000114420419010541/anip-20181231.xml#306235 Filing: 000114420419010541 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 1.08 million Exact value Exact value: -1076000 USD 2017-01-01 – 2017-12-31: -1076000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ANI PHARMACEUTICALS INC · 2017-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Net Income: -1076000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -1076000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000114420419010541/anip-20181231.xml#579329 Filing: 000114420419010541 The citation records this snapshot. The page link may show a newer release later.	USD 39.42 million Exact value Exact value: 39419000 USD 2017-01-01 – 2017-12-31: 39419000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ANI PHARMACEUTICALS INC · 2017-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Operating Cash Flow: 39419000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 39419000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000114420419010541/anip-20181231.xml#304861 Filing: 000114420419010541 The citation records this snapshot. The page link may show a newer release later.	USD 10.37 million Exact value Exact value: 10369000 USD 2017-01-01 – 2017-12-31: 10369000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ANI PHARMACEUTICALS INC · 2017-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Capital Expenditure: 10369000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 10369000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000114420419010541/anip-20181231.xml#306031 Filing: 000114420419010541 The citation records this snapshot. The page link may show a newer release later.	USD 29.05 million Calculation and evidence 39419000 − 10369000 USD Exact free cash flow: 29050000 USD 2017-01-01 – 2017-12-31: 39419000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 10369000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ANI PHARMACEUTICALS INC · 2017-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Free cash flow: 29050000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 39419000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000114420419010541/anip-20181231.xml#304861 Filing: 000114420419010541 Input fundies:CapitalExpenditure: 10369000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000114420419010541/anip-20181231.xml#306031 Filing: 000114420419010541 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	USD 15.49 million Exact value Exact value: 15494000 USD 2018-01-01 – 2018-12-31: 15494000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ANI PHARMACEUTICALS INC · 2018-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Net Income: 15494000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: 15494000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000114420419010541/anip-20181231.xml#579183 Filing: 000114420419010541 The citation records this snapshot. The page link may show a newer release later.	USD 67.07 million Exact value Exact value: 67074000 USD 2018-01-01 – 2018-12-31: 67074000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ANI PHARMACEUTICALS INC · 2018-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Operating Cash Flow: 67074000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 67074000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000114420419010541/anip-20181231.xml#305269 Filing: 000114420419010541 The citation records this snapshot. The page link may show a newer release later.	USD 5.74 million Exact value Exact value: 5743000 USD 2018-01-01 – 2018-12-31: 5743000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ANI PHARMACEUTICALS INC · 2018-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Capital Expenditure: 5743000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5743000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000114420419010541/anip-20181231.xml#306438 Filing: 000114420419010541 The citation records this snapshot. The page link may show a newer release later.	USD 61.33 million Calculation and evidence 67074000 − 5743000 USD Exact free cash flow: 61331000 USD 2018-01-01 – 2018-12-31: 67074000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 5743000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ANI PHARMACEUTICALS INC · 2018-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Free cash flow: 61331000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 67074000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000114420419010541/anip-20181231.xml#305269 Filing: 000114420419010541 Input fundies:CapitalExpenditure: 5743000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000114420419010541/anip-20181231.xml#306438 Filing: 000114420419010541 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 42.6 million Exact value Exact value: -42603000 USD 2021-01-01 – 2021-12-31: -42603000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ANI PHARMACEUTICALS INC · 2021-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Net Income: -42603000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -42603000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302424000026/anip-20231231.htm#1099806 Filing: 000102302424000026 The citation records this snapshot. The page link may show a newer release later.	USD 3.32 million Exact value Exact value: 3322000 USD 2021-01-01 – 2021-12-31: 3322000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ANI PHARMACEUTICALS INC · 2021-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Operating Cash Flow: 3322000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 3322000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302424000026/anip-20231231.htm#1267909 Filing: 000102302424000026 The citation records this snapshot. The page link may show a newer release later.	USD 2.56 million Exact value Exact value: 2557000 USD 2021-01-01 – 2021-12-31: 2557000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ANI PHARMACEUTICALS INC · 2021-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Capital Expenditure: 2557000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2557000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302424000026/anip-20231231.htm#1275480 Filing: 000102302424000026 The citation records this snapshot. The page link may show a newer release later.	USD 765,000 Calculation and evidence 3322000 − 2557000 USD Exact free cash flow: 765000 USD 2021-01-01 – 2021-12-31: 3322000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 2557000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ANI PHARMACEUTICALS INC · 2021-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Free cash flow: 765000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 3322000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302424000026/anip-20231231.htm#1267909 Filing: 000102302424000026 Input fundies:CapitalExpenditure: 2557000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302424000026/anip-20231231.htm#1275480 Filing: 000102302424000026 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 47.9 million Exact value Exact value: -47896000 USD 2022-01-01 – 2022-12-31: -47896000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ANI PHARMACEUTICALS INC · 2022-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Net Income: -47896000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -47896000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302425000015/anip-20241231.htm#1455173 Filing: 000102302425000015 The citation records this snapshot. The page link may show a newer release later.	−USD 31.2 million Exact value Exact value: -31203000 USD 2022-01-01 – 2022-12-31: -31203000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ANI PHARMACEUTICALS INC · 2022-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Operating Cash Flow: -31203000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -31203000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302425000015/anip-20241231.htm#1644864 Filing: 000102302425000015 The citation records this snapshot. The page link may show a newer release later.	USD 8.88 million Exact value Exact value: 8876000 USD 2022-01-01 – 2022-12-31: 8876000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ANI PHARMACEUTICALS INC · 2022-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Capital Expenditure: 8876000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 8876000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302425000015/anip-20241231.htm#1654026 Filing: 000102302425000015 The citation records this snapshot. The page link may show a newer release later.	−USD 40.08 million Calculation and evidence -31203000 − 8876000 USD Exact free cash flow: -40079000 USD 2022-01-01 – 2022-12-31: -31203000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 8876000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ANI PHARMACEUTICALS INC · 2022-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Free cash flow: -40079000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -31203000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302425000015/anip-20241231.htm#1644864 Filing: 000102302425000015 Input fundies:CapitalExpenditure: 8876000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302425000015/anip-20241231.htm#1654026 Filing: 000102302425000015 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	USD 18.78 million Exact value Exact value: 18779000 USD 2023-01-01 – 2023-12-31: 18779000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ANI PHARMACEUTICALS INC · 2023-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Net Income: 18779000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: 18779000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/anip-20251231.htm#1319717 Filing: 000102302426000014 The citation records this snapshot. The page link may show a newer release later.	USD 118.96 million Exact value Exact value: 118959000 USD 2023-01-01 – 2023-12-31: 118959000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ANI PHARMACEUTICALS INC · 2023-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Operating Cash Flow: 118959000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 118959000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/anip-20251231.htm#1501651 Filing: 000102302426000014 The citation records this snapshot. The page link may show a newer release later.	USD 8.87 million Exact value Exact value: 8868000 USD 2023-01-01 – 2023-12-31: 8868000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ANI PHARMACEUTICALS INC · 2023-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Capital Expenditure: 8868000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 8868000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/anip-20251231.htm#1508733 Filing: 000102302426000014 The citation records this snapshot. The page link may show a newer release later.	USD 110.09 million Calculation and evidence 118959000 − 8868000 USD Exact free cash flow: 110091000 USD 2023-01-01 – 2023-12-31: 118959000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 8868000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ANI PHARMACEUTICALS INC · 2023-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Free cash flow: 110091000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 118959000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/anip-20251231.htm#1501651 Filing: 000102302426000014 Input fundies:CapitalExpenditure: 8868000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/anip-20251231.htm#1508733 Filing: 000102302426000014 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 18.52 million Exact value Exact value: -18522000 USD 2024-01-01 – 2024-12-31: -18522000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ANI PHARMACEUTICALS INC · 2024-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Net Income: -18522000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -18522000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/anip-20251231.htm#1377146 Filing: 000102302426000014 The citation records this snapshot. The page link may show a newer release later.	USD 64.02 million Exact value Exact value: 64017000 USD 2024-01-01 – 2024-12-31: 64017000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ANI PHARMACEUTICALS INC · 2024-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Operating Cash Flow: 64017000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 64017000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/anip-20251231.htm#1501004 Filing: 000102302426000014 The citation records this snapshot. The page link may show a newer release later.	USD 16.24 million Exact value Exact value: 16236000 USD 2024-01-01 – 2024-12-31: 16236000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ANI PHARMACEUTICALS INC · 2024-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Capital Expenditure: 16236000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 16236000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/anip-20251231.htm#1508142 Filing: 000102302426000014 The citation records this snapshot. The page link may show a newer release later.	USD 47.78 million Calculation and evidence 64017000 − 16236000 USD Exact free cash flow: 47781000 USD 2024-01-01 – 2024-12-31: 64017000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 16236000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ANI PHARMACEUTICALS INC · 2024-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Free cash flow: 47781000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 64017000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/anip-20251231.htm#1501004 Filing: 000102302426000014 Input fundies:CapitalExpenditure: 16236000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/anip-20251231.htm#1508142 Filing: 000102302426000014 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	USD 78.34 million Exact value Exact value: 78337000 USD 2025-01-01 – 2025-12-31: 78337000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ANI PHARMACEUTICALS INC · 2025-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Net Income: 78337000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: 78337000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/anip-20251231.htm#1441778 Filing: 000102302426000014 The citation records this snapshot. The page link may show a newer release later.	USD 185.23 million Exact value Exact value: 185225000 USD 2025-01-01 – 2025-12-31: 185225000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ANI PHARMACEUTICALS INC · 2025-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Operating Cash Flow: 185225000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 185225000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/anip-20251231.htm#1500357 Filing: 000102302426000014 The citation records this snapshot. The page link may show a newer release later.	USD 13.84 million Exact value Exact value: 13835000 USD 2025-01-01 – 2025-12-31: 13835000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ANI PHARMACEUTICALS INC · 2025-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Capital Expenditure: 13835000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 13835000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/anip-20251231.htm#1507552 Filing: 000102302426000014 The citation records this snapshot. The page link may show a newer release later.	USD 171.39 million Calculation and evidence 185225000 − 13835000 USD Exact free cash flow: 171390000 USD 2025-01-01 – 2025-12-31: 185225000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 13835000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ANI PHARMACEUTICALS INC · 2025-12-31 ANI PHARMACEUTICALS INC (edgar:1023024) Free cash flow: 171390000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:40:36Z Snapshot: 4fdbfa9524d705c26bf30d720abe4f45f113e7e68aea15de4a0189a47d27301f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1023024?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 185225000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/anip-20251231.htm#1500357 Filing: 000102302426000014 Input fundies:CapitalExpenditure: 13835000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1023024/000102302426000014/anip-20251231.htm#1507552 Filing: 000102302426000014 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

212 filings · 7,181 latest values · 7,181 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001023024, 1023024, ANIP, edgar:1023024

Also known as ANI PHARMACEUTICALS INC, ANI PHARMACEUTICALS, INC, ANI PHARMACEUTICALS, INC., ANI PHARMACEUTICALS, INC, BEN ABRAHAM TECHNOLOGIES INC, BIOSANTE PHARMACEUTICALS INC

ANI PHARMACEUTICALS INC

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation